Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222878 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Phase 1 study of Alzheimer Disease and Epilepsy, sponsored by NeuroPro Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT07222878 is a Phase 1 study of Alzheimer Disease and Epilepsy that is actively recruiting participants, run by NeuroPro Therapeutics. The registered enrollment target is 8 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07222878, a Phase 1 study of Alzheimer Disease and Epilepsy, is actively recruiting participants, sponsored by NeuroPro Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
Conditions Studied
Interventions
- DRUG NPT 2042 (Reference formula/Formulation 1)
- DRUG NPT 2042 (Test formula/Formulation 2)
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2025-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222878
The ClinicalTrials.gov registry entry for NCT07222878 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is NeuroPro Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which NPT 2042 (Reference formula/Formulation 1) is the first listed.
NCT07222878 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT07222878 about?
NCT07222878 is a clinical study titled "Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042". A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
What is the current status of trial NCT07222878?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-09-29. Estimated completion is 2025-11-15.
What conditions does trial NCT07222878 study?
This clinical trial studies the following conditions: Alzheimer Disease, Epilepsy, Epilepsy Intractable.
What interventions are being tested in trial NCT07222878?
The interventions under investigation include: NPT 2042 (Reference formula/Formulation 1) (DRUG), NPT 2042 (Test formula/Formulation 2) (DRUG).
Who is sponsoring clinical trial NCT07222878?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222878 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
-
R21 Roche: 3-Way Tau Tracers in AD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.